儿童心室辅助装置患者的生存分析:儿科机械循环支持机构间登记(Pedimacs)专项报告
基于Pedimacs登记2012至2021年1109例19岁以下心室辅助装置(VAD)患者,采用Kaplan-Meier法分析生存、参数化风险模型识别死亡危险因素。6个月阳性结局为83%,植入式连续流装置92%、体外搏动式84%、体外连续流69%;经皮装置、婴儿、先天性心脏病、双心室支持及Interagency Registry for Mechanically Assisted Circulatory Support 1级患者6个月总生存更差。
要点
- 6个月阳性结局83%,植入式连续流92%高于体外搏动式84%与体外连续流69%。
- 经皮装置、婴儿、先天性心脏病、双心室支持及Interagency Registry for Mechanically Assisted Circulatory Support 1级患者6个月总生存更差。
- 参数化模型显示双心室支持、先天性心脏病、植入前插管、体外连续流装置及肾功能损害为早期死亡风险。
核心结论
- Pedimacs全数据库多变量分析表明,VAD植入时病情、诊断与支持策略影响生存,且随装置类型不同而异。
- 作者希望这是创建预测工具的第一步,帮助医务人员与家庭形成知情预期。
研究设计与样本
- Pedimacs登记分析,纳入2012至2021年年龄<19岁的患者,共1109例。
- 采用Kaplan-Meier法进行生存分析,并用参数化风险模型识别死亡危险因素。
主要发现
- 1109例中装置类型为植入式连续流448例(40%)、体外搏动式306例(28%)、体外连续流293例(26%)、经皮装置58例(5%)。
- 6个月阳性结局总体为83%,植入式连续流为92%、体外搏动式为84%、体外连续流为69%。
- 经皮装置、婴儿、先天性心脏病、双心室支持及Interagency Registry for Mechanically Assisted Circulatory Support 1级患者6个月总生存更差。
- 总生存参数化模型显示,双心室支持、先天性心脏病、植入前插管、体外连续流装置及肾功能损害对应早期死亡风险,腹水对应恒定风险。
- 体重<10 kg患者的参数化模型显示,先天性心脏病、插管及肾功能损害对应早期风险;先天性心脏病患者模型中,双心室支持、肾功能损害及使用体外连续流/体外搏动式装置对应早期风险。
关键数值与推荐
- 6个月阳性结局:总体83%;植入式连续流92%;体外搏动式84%;体外连续流69%。
- 总生存早期死亡风险因素:双心室支持、先天性心脏病、植入前插管、体外连续流装置、肾功能损害;腹水为恒定风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) provides detailed understanding on pediatric patients supported with ventricular assist devices (VADs). We sought to identify important variables affecting mortality in pediatric VADs. METHODS: Patients aged <19 years, from 2012 to 2021, were included. Survival analyses were performed using Kaplan-Meier. Parametric hazard modeling was used to identify risk factors for death. RESULTS: Of the 1109 patients, the most common devices were implantable continuous (IC, 448 [40%]), followed by paracorporeal pulsatile (PP, 306 [28%]), paracorporeal continuous (PC, 293 [26%]), and percutaneous (58 [5%]). Patients with percutaneous device, infants, congenital heart disease, biventricular support, and Interagency Registry for Mechanically Assisted Circulatory Support profile 1 had worse overall survival at 6 months. Positive outcome was 83% at 6 months. Consistent with their cohort composition, device type positive outcomes at 6 months were IC, 92%; PP, 84%; and PC, 69%. Parametric hazard modeling for overall survival showed an early hazard for death with biventricular support, congenital heart disease (CHD), intubation before implantation, PC device, and renal impairment, whereas a constant hazard was associated with ascites. For patients <10 kg, parametric modeling showed an early hazard for CHD, intubation, and renal impairment. Modeling in CHD patients showed an early hazard for biventricular support, renal impairment, and use of PC/PP devices. CONCLUSIONS: This multivariable analysis of the complete Pedimacs database demonstrates that illness at VAD implantation, diagnosis, and strategy of support affect survival and differ by device type. We hope this is the first step in creating a predictive tool to help providers and families have informed expectations.
引用
- Ashfaq A, Lorts A, Rosenthal D, et al. Survival in Pediatric Patients With Ventricular Assist Devices: A Special Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report. Ann Thorac Surg. 2023. PMID: 37573991. doi:10.1016/j.athoracsur.2023.07.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。